The Daily Biotech Pulse: CHMP Backs AstraZeneca’s Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours:
With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
Key Takeaways:
Laekna is seeking a Hong Kong IPO to raise funds to accelerate the commercialize two core products licensed from Novartis
The company currently is not generating any sale, with most of its products in early stages of development
By Tina Yip
Sanofi-GSK’s Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine…
Antibiotic Makers Adopt Their Own Environmental Safeguard Standards
The AMR Industry Alliance, a life-sciences coalition set up to provide sustainable solutions to curb antimicrobial resistance (AMR),…
Sanofi-GSK’s Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern
Sanofi SA (NASDAQ:SNY) said the next-gen COVID-19 vaccine candidate it has developed with GSK Plc (NASDAQ:GSK) in two trials showed a…
Morning Brief: Top Financial Stories Dominating on Friday, June 10
Reuters
Rebranded McDonald’s Restaurants To Reopen In Russia
GSK Shows Positive Pivotal Phase III Data For Its RSV Vaccine Candidate
GSK plc (NYSE:GSK) intends to engage with regulators immediately after reporting positive headline results from a pre-specified efficacy interim analysis…
GSK Announces FDA Approval Of PRIORIX For The Prevention Of Measles, Mumps And Rubella In Individuals 12 Months Of Age And Older
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
PRIORIX becomes an additional source of measles, mumps and rubella vaccine for US
FDA Approves GSK’s Measles Vaccine
The FDA has approved GSK Plc’s (NYSE:GSK) Priorix vaccine to prevent measles, mumps, and rubella (MMR) in those aged one year…